Oncostellae

Pipeline

Pipeline

OST-122 Oral, GI-restricted JAK3/TYK2-ARK5 inhibitor IBD (fibrosis, CRC)
DISCOVERY 100%
OPTIMIZATION 100%
PRECLINICAL 100%
PHASE I 18%
OST-246 Oral, systemic JAK3/TYK2-MLK3 inhibitor Autoinmune dis.
DISCOVERY 100%
OPTIMIZATION 100%
PRECLINICAL 0%
PHASE I 0%
OST-428 Oral GR antagonist I/O, CRPC
DISCOVERY 100%
OPTIMIZATION 100%
PRECLINICAL 0%
PHASE I 0%